Home >> Research Area >>Natural Products>>Diterpenoids>> 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

CAS# 195735-16-1

2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

Catalog No. BCN1509----Order now to get a substantial discount!

Product Name & Size Price Stock
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside: 5mg Please Inquire In Stock
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside: 10mg Please Inquire In Stock
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside: 20mg Please Inquire Please Inquire
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside: 50mg Please Inquire Please Inquire
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside: 100mg Please Inquire Please Inquire
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside: 200mg Please Inquire Please Inquire
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside: 500mg Please Inquire Please Inquire
2,6,16-Kauranetriol 2-O-beta-D-allopyranoside: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

Number of papers citing our products

Chemical structure

2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

3D structure

Chemical Properties of 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

Cas No. 195735-16-1 SDF Download SDF
PubChem ID 91668402 Appearance Powder
Formula C26H44O8 M.Wt 484.6
Type of Compound Diterpenoids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name (2R,3R,4R,5S,6R)-2-[[(1R,3R,4R,7R,9S,10R,13R,14R)-3,14-dihydroxy-5,5,9,14-tetramethyl-7-tetracyclo[11.2.1.01,10.04,9]hexadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES CC1(CC(CC2(C1C(CC34C2CCC(C3)C(C4)(C)O)O)C)OC5C(C(C(C(O5)CO)O)O)O)C
Standard InChIKey RGKNTHMUHXNDHJ-GMOWVNSKSA-N
Standard InChI InChI=1S/C26H44O8/c1-23(2)8-14(33-22-20(31)19(30)18(29)16(11-27)34-22)9-24(3)17-6-5-13-7-26(17,12-25(13,4)32)10-15(28)21(23)24/h13-22,27-32H,5-12H2,1-4H3/t13-,14-,15-,16-,17+,18-,19-,20-,21-,22-,24+,25-,26-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

The herbs of Pteris cretica

2,6,16-Kauranetriol 2-O-beta-D-allopyranoside Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

2,6,16-Kauranetriol 2-O-beta-D-allopyranoside Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.0636 mL 10.3178 mL 20.6356 mL 41.2712 mL 51.5889 mL
5 mM 0.4127 mL 2.0636 mL 4.1271 mL 8.2542 mL 10.3178 mL
10 mM 0.2064 mL 1.0318 mL 2.0636 mL 4.1271 mL 5.1589 mL
50 mM 0.0413 mL 0.2064 mL 0.4127 mL 0.8254 mL 1.0318 mL
100 mM 0.0206 mL 0.1032 mL 0.2064 mL 0.4127 mL 0.5159 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

Synthesis, Cytotoxic and Anti-proliferative Activity of Novel Thiophene, Thieno[2,3-b]pyridine and Pyran Derivatives Derived from 4,5,6,7-tetrahydrobenzo[b]thiophene Derivative.[Pubmed:28380235]

Acta Chim Slov. 2017 Mac;64(1):117-128.

Novel tetrahydrobenzo[b]thienopyrole derivatives are synthesized from 2-amino-3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophene (1) through its reaction with alpha-chloroacetone to give the corresponding N-alkyl derivative 3. Compound 3 undergoes ready cyclization in sodium ethoxide solution to give the tetrahydrobenzo[b]thienopyrrole 4. The latter compound 4 is used as the key starting material for the synthesis of thiophene, thieno[2,3-b]pyridine and pyran derivatives. The cytotoxicity of the synthesized products towards the human cancer cell lines namely gastric cancer (NUGC), colon cancer (DLD-1), liver cancer (HA22T and HEPG-2), breast cancer (MCF-7), nasopharyngeal carcinoma (HONE-1) and normal fibroblast (WI-38) cell lines are measured. Compounds 4, 7a, 7b, 8a, 8b, 10c, 10d, 10f, 12a, 12b, 14b and 15b exhibit the optimal cytotoxic effect against cancer cell lines. Compounds 7b and 14b show the maximum inhibitory effect and these are much higher than the reference CHS-828 (pyridyl cyanoguanidine). On the other hand, the anti-proliferative evaluations of these compounds with high potency against the cancer cell lines L1210, Molt4/C8, CEM, K562, K562/4 and HCT116 show that compounds 7b and 8b give IC50's against Molt4/C8 and CEM cell lines higher than that of the reference, doxorubicin.

Structural and Functional State of Erythrocyte Membranes in Mice at Different Stages of Experimental Parkinson's Disease Induced by Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP).[Pubmed:28382410]

Bull Exp Biol Med. 2017 Mar;162(5):597-601.

We studied some structural and functional parameters of erythrocyte membranes in mice at the late presymptomatic and early symptomatic stages of experimental Parkinson's disease induced by administration of MPTP (hemolysis, microviscosity of different regions of the lipid bilayer, LPO intensity, activity of antioxidant enzymes, and kinetic properties of acetylcholinesterase). At the presymptomatic stage, significant deviations of the studied parameters from the normal were observed; they were similar in direction and magnitude to those in humans with Parkinson's disease. At the early symptomatic stage, most parameters tended to normal. Microviscosity of bulk lipids increased at the presymptomatic stage and decreased after appearance of clinical symptoms. This dynamics probably reflects activation of compensatory mechanisms aimed at inhibition of oxidative stress triggered by the development of the pathological process.

Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIalpha dual inhibitors with DNA non-intercalative catalytic activity.[Pubmed:28384547]

Eur J Med Chem. 2017 Jun 16;133:69-84.

With the aim to develop novel antiproliferative agents, a new series of eighteen dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines were systematically designed, prepared, and investigated for their topoisomerase (topo) I and IIalpha inhibitory properties and antiproliferative effect in three different human cancer cell lines (HCT15, T47D, and HeLa). Compounds 22-30 which possess a meta- or para-phenol on 2-, or 6-position of central pyridine ring showed significant dual topo I and topo IIalpha inhibitory activities with strong antiproliferative activities against all the tested human cancer cell lines. However, compounds 13-21 which possess an ortho-phenol on 2-, or 6-position of central pyridine ring did not show significant topo I and topo IIalpha inhibitory activities but displayed moderate antiproliferative activities against all the tested human cancer cell lines. Compound 23 exhibited the highest antiproliferative potency as much as 348.5 and 105 times compared to etoposide and camptothecin, respectively, in T47D cancer cell line. The structure-activity relationship study revealed that the para position of a hydroxyl group at 2-and 6-phenyl ring and chlorine atom at the para position of 4-phenyl ring of the central pyridine exhibited the most significant topo I and topo IIalpha inhibition, which might indicate introduction of the chlorine atom at the phenyl ring of 4-pyridine have an important role as dual inhibitors of topo I and topo IIalpha. Compound 30 which showed the most potent dual topo I and topo IIalpha inhibition with strong antiproliferative activity in T47D cell line was selected to perform further study on the mechanism of action, which revealed that compound 30 functions as a potent DNA non-intercalative catalytic topo I and IIalpha dual inhibitor.

A Novel Methodology for Synthesis of 1,5,6-Trisubstituted 2(1H)-Pyrazinones of Biological Interest.[Pubmed:28381677]

Chem Pharm Bull (Tokyo). 2017;65(4):365-372.

In this report, we describe a new method for the synthesis of densely functionalized 2(1H)-pyrazinones. Treatment of mesoionic 1,3-oxazolium-5-olates with carbanions derived from activated methylene isocyanides (p-toluenesulfonylmethyl isocyanide (TosMIC) and ethyl isocyanoacetate) causes a novel ring transformation affording 2(1H)-pyrazinones in moderate to high yields. The cytotoxicity and antibacterial activity of some of the obtained products were studied and some of the products exhibited tumor-specific cytotoxicity.

Keywords:

2,6,16-Kauranetriol 2-O-beta-D-allopyranoside,195735-16-1,Natural Products, buy 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside , 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside supplier , purchase 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside , 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside cost , 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside manufacturer , order 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside , high purity 2,6,16-Kauranetriol 2-O-beta-D-allopyranoside

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: